IRLAB Therapeutics Valuation
Is IRLAB A undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for IRLAB A?
Other financial metrics that can be useful for relative valuation.
|What is IRLAB A's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does IRLAB A's PE Ratio compare to its peers?
|IRLAB A PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
CAU Cronos Australia
PRPH ProPhase Labs
IRLAB A IRLAB Therapeutics
Price-To-Earnings vs Peers: IRLAB A is expensive based on its Price-To-Earnings Ratio (40.5x) compared to the peer average (35.8x).
Price to Earnings Ratio vs Industry
How does IRLAB A's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?
Price-To-Earnings vs Industry: IRLAB A is expensive based on its Price-To-Earnings Ratio (40.5x) compared to the European Pharmaceuticals industry average (17.1x)
Price to Earnings Ratio vs Fair Ratio
What is IRLAB A's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||40.5x|
|Fair PE Ratio||19.2x|
Price-To-Earnings vs Fair Ratio: IRLAB A is expensive based on its Price-To-Earnings Ratio (40.5x) compared to the estimated Fair Price-To-Earnings Ratio (19.2x).
Share Price vs Fair Value
What is the Fair Price of IRLAB A when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate IRLAB A's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate IRLAB A's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.